

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A formulation comprising at least one hybridoma having at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is ~~selected from the group consisting of a tumor cell and~~ a virally infected cell.

2. (Currently Amended) The formulation of ~~Claim~~ claim 1, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through in vitro culture of precursors.

3. (Canceled).

4. (Currently Amended) The formulation of ~~Claim~~ claim 1, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.

5. (Currently Amended) The formulation of ~~Claim~~ claim 1, wherein said hybridoma contains a ratio of first cells to second cells between about 1:100 and 100:1.

6. (Currently Amended) The formulation of ~~Claim~~ claim 1, wherein said hybridoma contains a ratio of first cells to second cells of between about 1:10 and 10:1.

7. (Currently Amended) The formulation of ~~Claim~~ claim 1, wherein said hybridoma contains a ratio of first cells to second cells of about 6:1.

8. (Currently Amended) A pharmaceutical composition comprising: at least one hybridoma; and a suitable pharmaceutical carrier; wherein each hybridoma is comprised of at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is ~~selected from the group consisting of a tumor cell and a virally infected cell.~~

9. (Currently Amended) The pharmaceutical composition of ~~Claim~~ claim 8, wherein said suitable pharmaceutical carrier is selected from the group consisting of saline and phosphate buffered saline.

10. (Currently Amended) The pharmaceutical composition of ~~Claim~~ claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:100 and 100:1.

11. (Currently Amended) The pharmaceutical composition of ~~Claim~~ claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:10 and 10:1.

12. (Currently Amended) The pharmaceutical composition of ~~Claim~~ claim 9, wherein said hybridomas have a ratio of first cells to second cells of about 6:1.

13-36. (Canceled).